GSK Says Linerixibat Accepted For Priority Review In China
ReutersFeb 26, 2026 7:23 AM
Feb 26 (Reuters) - GSK plc GSK.L:
GSK PLC - LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Circle Stock Price Outlook: Will Circle Internet Group Rebound in 2026?
TradingKey - Circle Internet Group (CRCL) saw its stock price experience a roller coaster ride since its 2025 IPO debut at $31 a share. Those early fireworks faded, and the shares now sit roughly 75% below their June peak, though they’re still more than double the IPO level. Outside of that first-moTradingKey
20 hours ago
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.TradingKey
Wed, Feb 25
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.TradingKey
Tue, Feb 24
What Is the Best Nuclear Energy Investment in 2026? Which Should You Buy in, OKLO or Nuclear Energy ETFs?
TradingKey - Demand for electricity is surging, and data centers designed for artificial intelligence are a big reason. Governments are also demanding cleaner, dependable power. This coupling has brought about a revival in nuclear power, with capacity expected to increase in the coming decades. To iTradingKey
Fri, Feb 20
